- Change of heart
HEADNOTE Edwards Readies for New Era of Heart Valves, Less Major Surgery IMAGE PHOTOGRAPH 1 Foster: "This is not a threat to our business" Heart valve maker Edwards Lifesciences Corp. of Irvine is readying for a world where heart surgery isn't what it used to be. Edwards, with the largest ......
- The latest words in cardiac care: 'Minimally invasive'
Did you know that cardiovascular disease claimed 910,614 lives - one of every 2.7 deaths - in 2003?
- Healthcare
HEADNOTE Edwards Sells German Unit in Perfusion Divestiture FDA Panel Studies Micro Therapeutics' Onyx; OC Hospitals Part of Coronary Network Edwards Lifesciences Corp., the Irvine-based heart device maker, plans to sell its German perfusion services unit to WKK GmbH of Mainz, Germany. Terms of the deal weren't disclosed. The Edwards ......
- Heart valve inserted in trial via
catheter.
A team of Michigan cardiac surgeons said they inserted an Edwards Lifesciences Corp. valve into the first American patient as part of a clinical trial. The development is considered a critical phase for a product that officials at the Irvine-based company hope will play a key role in future heart ......
- Healthcare
HEADNOTE Edwards Picks Up Heart Surgery Blood Filter From Embol-X Healthy Smiles Plans Kids' Dental Service; Hoag Offering Drug-Coated Stent, High-Speed Internet Irvine's Edwards Lifesciences Corp. has bought a product line designed to keep blood clots and tissue pieces from entering the bloodstream during surgery. About two weeks ago, Edwards ......
- Heart Valve Startup Raises $20M for Device Trial
Arbor Surgical Technologies Inc., an Irvine-based heart valve maker, has raised $20 million in a second round of venture funding. The funding includes money from prior investor Johnson & Johnson and was led by Baird Venture Partners, a unit of Milwaukeebased R. W. Baird & Co. Three Arch Partners of ......
- Medtronic to acquire VidaMed Inc. for 39.7 times revenue
The Deal: Medtronic Inc. has agreed to acquire VidaMed Inc. in a cash deal valued at $326 million. Upon completion of the transaction, each VidaMed shareholder will receive $7.91 per share. The deal still requires approval from shareholders, and is expected to close during the first quarter of 2002. Discussion: ......